You are here
Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors
PETALUMA, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today announced the appointment of Philippe Weigerstorfer to the company’s board of directors.
Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma’s board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel.
In 1999, Weigerstorfer joined Galencia Ltd’s executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market and with the acquisition of Canada-based Aspreva, in effectively forming Vifor Pharma Ltd in 2008. At Vifor he was responsible for the business development, licensing and M&A activities while based in Canada, and then based in Singapore, heading the regional operations in Asia Pacific as well as in the Middle East, the Commonwealth of Independent States, Africa, and Latin America.
“We’re excited to add Philippe’s vast pharmaceutical, dermatology and international experience to our board of directors,” said Jim Schutz, Sonoma CEO. “We expect his knowledge of our core strategic dermatology business along with his broad pharmaceutical experience will be highly valued as we look to continue our rapid growth.”
Weigerstorfer will replace Russ Harrison who is retiring from Sonoma’s board of directors after four and a half years of service.
“We’d like to thank Russ for his contributions to the board as he helped orchestrate a new strategy for the company, which included restructuring and refocusing the company to better target the high-profitable dermatology space. Personally, I’d like to thank Russ for his many years of mentoring me and his demonstrative leadership style,” said Schutz.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “expect,” and “continue,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals® is a registered trademark of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.